{"id":4528,"date":"2025-03-31T18:12:11","date_gmt":"2025-03-31T18:12:11","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/imidapril-hydrochloride-txt\/"},"modified":"2025-03-31T18:12:11","modified_gmt":"2025-03-31T18:12:11","slug":"imidapril-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/imidapril-hydrochloride-txt\/","title":{"rendered":"imidapril hydrochloride.txt"},"content":{"rendered":"

imidapril hydrochloride <\/h1>\n

CLINICAL USE <\/H3>
\nAngiotensin-converting enzyme inhibitor:Hypertension

DOSE IN NORMAL RENAL FUNCTION <\/H3>2.5\u201320 mg once daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :441.9<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :85<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 9 (as imidaprilat)<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :No data<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2\/Increased (>24 hours as imidaprilat)

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Initially 2.5 mg daily and adjust according to response
  • 10 to 20 &nbsp &nbsp : Initially 2.5 mg daily and adjust according to response
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Initially 2.5 mg daily and adjust according to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Probably dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Probably dialysed. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect\n
  • Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs\n
  • Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity\n
  • Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics\n
  • Epoetin: increased risk of hyperkalaemia; antagonism of hypotensive effect\n
  • Lithium: reduced excretion, possibility of enhanced lithium toxicity\n
  • Potassium salts: increased risk of hyperkalaemia\n
  • Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Imidapril is a prodrug, rapidly converted to the active imidaprilatHyperkalaemia and other side effects are more common in patients with impaired renal functionClose monitoring of renal function during therapy is necessary in those with renal insufficiencyRenal failure has been reported in association with ACE inhibitors with renal artery stenosis, post renal transplant or congestive heat failureHigh incidence of anaphylactoid reactions have been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor \u2013 combination should therefore be avoided
    \n","protected":false},"excerpt":{"rendered":"

    imidapril hydrochloride CLINICAL USE Angiotensin-converting enzyme inhibitor:Hypertension DOSE IN NORMAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4528","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4528"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4528\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}